Efficacy of macrolides vs. metronidazole against Entamoeba histolytica clinical isolates

Wiener Klinische Wochenschrift

Volumn 113, Issue 15-16, 2001, Pages 593-596

  Georgopoulos, Apostolos ^c   Linnau, Kenn F ^d   Buxbaum, Astrid ^a   Coste, Carmen ^a   Ramirez De Los Santos, Marta Ana ^b   Shabpar, Anita ^d   Graninger, Wolfgang ^d  

^a Laboratory   (Dominican Republic)

^b Hospital Santa Anita   (El Salvador)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d NONE

Author keywords

Activity; Entamoeba histolytica; Macrolides; Metronidazole; MIC

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE; METRONIDAZOLE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DOMINICAN REPUBLIC; DOSE RESPONSE; DRUG EFFECT; DYSENTERY; ENTAMOEBA HISTOLYTICA; FECES; FEMALE; HUMAN; MALE; PARASITOLOGY; PREGNANCY;

ANIMALS; ANTI-BACTERIAL AGENTS; DOMINICAN REPUBLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSENTERY, AMEBIC; ENTAMOEBA HISTOLYTICA; FECES; FEMALE; HUMANS; MACROLIDES; MALE; METRONIDAZOLE; PREGNANCY;

EID: 0035899672     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Radvin JI (1995) Amebiasis; state-of-the-art clinical article. Clin Infect Dis 20: 1453-1464
2. Walsh JA (1986) Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev Infect Dis 8: 228-238
3. Robbie MO, Sweet RL (1983) Metronidazole use in obstetrics and gynecology: a review. Am J Obstet Gynecol 145: 865-881
4. Reitz M, Rumpf M, Knitza R (1991) DNA single strandbreaks in lymphocytes after metronidazole therapy. Drug Res 41: 155-156
5. Elizondo G, Montera R, Herrera JE, Hong E, Ostrosky-Wegman P (1994) Lymphocyte proliferation kinetics and sister-chromatid exchanges in individuals treated with metronidazole. Mutation Res 305: 133-137
6. Elizondo G, Gonsbatt ME, Salazar AM, Lares I, Santiago P, Herrera J (1996) Genotoxic effects of metronidazole. Mutation Res 370: 75-80
7. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23: 328-364
8. Mudry MD, Carballo M, Labal de Vinuesa M, Gonzalez Cid M, Larripa I (1994) Mutagenic bioassay of certain pharmacological drugs: III. metronidazole. Mutation Res 305: 127-132
9. Ikerd TR, Koletar SL (1993) In-vitro activity of ciprofloxacin, temafloxacin, azithromycin, clarithromycin and metronidazole against Giardia lamblia. J Antimicrob Chemother 31: 615-617 (Letter)
10. Cedeno JR, Krogstad DJ (1983) Susceptibility testing of Entamoeba histolytica. J Inf Dis 148: 1090-1095
11. Radvin JI, Skilogiannis J (1989) In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazol. Antimicrob Agents Chemother 33: 960-962
12. Robinson GL (1968) The laboratory diagnosis of human parasitic amoebae. Trans R Soc Trop Med Hyg 62: 285-294
13. Bracha R (1990) Differentiation of clinical isolates of Entamoeba histolytica by using specific DNA probes. J Clin Microbiol 28: 680-684
14. Spice WM, Ackers JP (1990) Large-scale production of Entamoeba hisrolytica trophozoites in polyxenic culture. Trans R Soc Trop Med Hyg 84: 693-694
15. Diamond LS (1968) Techniques of axenic cultivation of Entamoeba histolytica Schaudinn, 1903 and E. histolyticalike amebae. J Parasitol 54: 1047-1056
16. Diamond LS (1978) A new medium for axenic cultivation of Entamoeba histolytica and other entamoebae. Trans R Soc Trop Med Hyg 72: 431-432
17. Aguirre-Cruz ML, Valadez-Salazar A, Munoz O (1990) In vitro sensitivity of Entamoeba histolytica to metronidazol. Arch Invest Med 21 [Suppl]: 23-26
18. Calzado-Flores CC, Segura JJ, Flores-Villanueva Z (1991) In vitro study of different antiamoebic drugs. Proc West Pharmacol Soc 34: 355-358
19. Chavez B, Espinosa-Cantellano M, Cedillo Rivera R, Martinez-Palomo A (1992) Effects of albendazole on Entamoeba histolytica and Giardia lamblia trophozoites. Arch Med Res 23: 63-67
20. Periti P, Mazzei T, Mini E, Novelli A (1993) Adverse effects of macrolide antibacterials. Drug Safety 9: 346-364
21. Eichenwald HF (1986) Adverse reactions to erythromycin. Ped Inf Dis 5: 147-150
22. Schwebke JR (1995) Metronidazole: utilisation in the Obstetric and gynecologic patient. Sex Transm Dis 22: 370-376
23. Mirelman D (1987) Ameba-bacterium relationship in amebiasis. Microbiol Rev 51: 272-284
24. Gupta RL, Vats V, Juneja TR (1996) Activation of tinidazole, an antiprotozoal drug to a mutagen by mammalian liver S9. Mutation Res 370: 195-201
25. Piper JM, Mitchel EF, Ray WA (1993) Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 82: 348-352